Does Reducing Spasticity Permit an Increase in Strength?
|ClinicalTrials.gov Identifier: NCT00255073|
Recruitment Status : Completed
First Posted : November 17, 2005
Last Update Posted : May 23, 2014
Reduction of spasticity has been a major focus of the treatment of childhood cerebral palsy, resulting in numerous treatment strategies that target various parts of the motor system. However, in many children weakness may be a greater contributor to disability than spasticity. Recent results suggest a correlation between spasticity and weakness, but it is not known if reduction of spasticity can improve strength.
We suggest a simplified model in which spinal mechanisms (including reflex contributions to spasticity) and supraspinal mechanisms (including voluntary contributions to strength) combine to activate muscle. The model implies that the supraspinal contribution cannot increase unless the spinal contribution decreases. We therefore hypothesize that reduction of spasticity improves the ability to increase voluntary strength.
We propose a double-masked placebo-controlled clinical trial combining treatment using the oral anti-spasticity medication baclofen with a 6-week program of strength training. We will enroll 20 ambulatory children with spastic diplegic cerebral palsy. Prior to and following the intervention, we will obtain quantitative measures of spasticity, strength, and gait. We predict that the children taking baclofen will have a greater increase in strength than the children taking placebo. We predict that the increase in strength will be reflected in improved performance on gait analysis, and it will correlate with a reduction in quantitative measures of spasticity and spinal reflex excitability.
If the hypothesis is correct, it will provide important new information on the relationship between spasticity and strength in children with cerebral palsy. It will provide the first measurements of the effect of baclofen on voluntary muscle activation in children. It will support the short-term use of combined anti-spasticity medication and strengthening as a new clinical treatment for ankle weakness in children with spastic diplegia. A successful result will have immediate and significant implications for treatment of children with cerebral palsy.
|Condition or disease||Intervention/treatment||Phase|
|Spastic Diplegic Cerebral Palsy||Drug: baclofen||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Does Reducing Spasticity Permit an Increase in Strength?|
|Study Start Date :||January 2005|
|Study Completion Date :||April 2006|
- Maximal Voluntary Contraction
- H reflex
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00255073
|United States, California|
|Stanford, California, United States, 94305-5235|
|Principal Investigator:||Terence Sanger, md,phd||Stanford University|